Posted by Michael Wonder on 26 Dec 2021
Novartis Cosentyx receives FDA approval for the treatment of children and adolescents with enthesitis related arthritis and psoriatic arthritis
22 December 2021 - New approvals are based on JUNIPERA trial data showing Cosentyx (secukinumab) demonstrated reduced flare risk versus placebo and improvement in disease activity observed over two years across both enthesitis related arthritis and psoriatic arthritis in paediatric patients.
Novartis today announced the US FDA has approved Cosentyx (secukinumab) for the treatment of active enthesitis related arthritis in patients four years and older, and active psoriatic arthritis in patients two years and older.
